menu
    • menu
    [{"orgOrder":0,"company":"Vaxess","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MIMIX-flu Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxess \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxess \/ Inapplicable"},{"orgOrder":0,"company":"Vaxess","sponsor":"GC Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VX-103","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Microneedle Patch, Controlled Release","sponsorNew":"Vaxess \/ GC Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Vaxess \/ GC Pharma"},{"orgOrder":0,"company":"Vaxess","sponsor":"National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Patch","sponsorNew":"Vaxess \/ National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vaxess \/ National Science Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Vaxess

    Menu

    Vaxess

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vaxess

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Vaxess

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIMIX-flu Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vaxess Announces Interim Results from Phase I Clinical Trial of MIMIX-Flu Vaccine Patch

                            Details : VX-103 (MIMIX-flu vaccine ) were well tolerated, with no serious or severe adverse events. The overall rate of reported systemic events was favorable as compared to traditional vaccines delivered by needle and syringe.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 14, 2022

                            Lead Product(s) : MIMIX-flu Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vaxess

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Vaxess

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VX-103

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : GC Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vaxess Announces Production of The First GMP Batch of MIMIX™ Technology Vaccine Patches for an Upcoming Phas...

                            Details : In preclinical studies of MIMIX-Flu, combines GC’s commercial seasonal influenza vaccine antigen with Vaxess’s innovative MIMIX patch-based intradermal controlled release delivery system, have demonstrated dose sparing and improved immunogenicity.

                            Product Name : MIMIX-Flu

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 04, 2022

                            Lead Product(s) : VX-103

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : GC Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vaxess

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Vaxess

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-Based COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : National Science Foundation

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Fre...

                            Details : Funding will be used to integrate mRNA-based vaccines and gene modulators provided through a collaboration with the Santangelo Lab at Georgia Tech into MIMIX patches to improve the efficacy and administration of novel mRNA-based vaccines and other medica...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 22, 2021

                            Lead Product(s) : mRNA-Based COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : National Science Foundation

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth